Low-Temperature Synthesis of Silicon Oxynitride-Doped Si for Tunable Bragg Gratings Homogeneously Deposited on Si, SiO2, and Borosilicate Substrates and the tip of SM and PM Optical Fibers

Optical tunability and repeatability are essential in fabricating optoelectronic devices from waveguides to Bragg gratings (BGs) for high-energy, high-power, mode-locking, and sensing applications. For this purpose, a controlled adjustment in the optical properties, including the refractive index of the deposited nanolayers, becomes critical. This study reveals that silicon oxynitride (SiON) doping into silicon (Si) offers a new way for the preparation of novel Si-based devices with an emphasis on the BGs for filtering a particular portion of an electromagnetic spectrum, including the wavelengths of 800, 976, 1550, and 1840 nm. Control on the incident angle dependence of the BGs was demonstrated at Watt-level for the wavelength of 976 nm. Amorphous SiON-doped Si layers on alternating SiO2 can be synthesized on bulk substrates and different optical fibers at relatively low temperatures with wide and narrow bandwidths. The high reflectivity of the novel Si-based BGs reveals over −22 dB reflection using typical optical fibers, including standardsingle-mode fibers and high-birefringent polarization-maintaining (PM) fibers. The polarized transmission measurement over the BG on the PMfiber shows the BGs do not deteriorate the PM properties, strongly yielding a beat length of 1.68 mm and birefringence of 9.2 × 10−4 at the telecom C band

Phase-Shifted Bragg-Grating Consisting of Silicon Oxynitride Doped Silicon and Silica Alternating Layers Lab-on-Fiber for Biosensors with Ultrahigh Sensitivity and Ultralow Detection Limit

Fabry-Perot (FP) optical fiber sensors are reported to be highly sensitive for detecting various physical, chemical, and biological objects. In this study, an FP-based Phase Shifted Bragg-Grating Lab-on-Fiber (PSBG-LOF) is presented to determine ultralow glucose concentrations in liquids by using a novel PSBG at the end facet of a single-mode fiber (SMF). The proposed LOF consists of an intermediate silica layer sandwiched between two identical PSBGs formed by 4.5 pairs of siliconoxynitrite (SiON) doped silicon (Si), which are newly synthesized silica (SiO2) thin films, all deposited by the plasma enhanced chemical vapor deposition (PECVD) method. The SiON-doped Si molecule group was used for the first time as PSBG structures and LOF of the glucose in liquids. Our findings with the proposed sensors revealed that the sensitivity value was 14904 nm/RIU (4.3 pm/ppm and 4.29 nm/(mg/ml)) and the detection limit was calculated as 1.98 × 10−6 RIU. In addition, the proposed sensor is insensitive to temperature changes in the range of 25°C-45°C. The results are very promising for the in-vivo biosensing applications comprising temperature unresponsive LOF

Pulmonary physician consultancy in emergency services in Turkey (PUPCEST) - a prospective multicenter study

28th International Congress of the European-Respiratory-Society (ERS) -- SEP 15-19, 2018 -- Paris, FRANCEYILDIZ, Hanifi/0000-0003-0735-5034;WOS: 000455567102422…European Respiratory So

Clinical characteristics and outcomes of nosocomial COVID-19 in Turkey: A retrospective multicenter study

Objective: To identify the clinical characteristics and outcomes of hospital-acquired SARS-CoV-2 infection during the vaccination period nationwide in Turkey. Methods: COVID-19 patients followed in the pandemic services across Turkey between January 1, 2021, and March 31, 2022 were investigated retrospectively. Nosocomial COVID-19 was defined as a patient neither diagnosed with COVID-19 nor suspected COVID-19 at the hospital admission and was confirmed COVID-19 ≥5 days after hospital admission. The primary outcome of this study was in-hospital mortality; demographic features and vaccination status was compared between survivors and non-survivors. Results: During the study period, 15 573 COVID-19 patients were followed in 18 centers and 543 (3.5%) patients were nosocomial COVID-19. Most patients with nosocomial COVID-19 (80.4%) were transferred from medical wards. 162 (29.8%) of the patients with nosocomial COVID-19 admitted to the intensive care unit due to disease severity and 138 (25.4%) of the patients died during hospital stay. Advanced age (≥65 years) and number of comorbid diseases (≥2) was found to be associated with mortality in nosocomial COVID-19 (OR 1.74, 95% Cl 1.11-2.74 and OR 1.60, 95% Cl 1.02-2.56, respectively). Vaccination was associated with survival in nosocomial COVID-19 (OR 0.25, 95% Cl 0.16-0.38). Conclusions: Patients with nosocomial COVID-19 had increased admission to intensive care units and higher mortality rate. Vaccination can decrease the in-hospital mortality rate

Frequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)

Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice